Study identification

PURI

https://redirect.ema.europa.eu/resource/1000000530

EU PAS number

EUPAS1000000530

Study ID

1000000530

Official title and acronym

Assessing the impact of earlier access to biologics on remission and natural course of asthma (GLEAM)

DARWIN EU® study

No

Study countries

Argentina
Belgium
Brazil
Bulgaria
Canada
Colombia
Denmark
Estonia
Greece
India
Ireland
Italy
Japan
Korea, Republic of
Kuwait
Mexico
Norway
Poland
Portugal
Saudi Arabia
Singapore
Spain
Taiwan
United Arab Emirates
United Kingdom
United States

Study description

An examination of the association between the timing of biologic therapy initiation, disease progression, and remission probabilities in severe asthma.

Study status

Ongoing
Research institutions and networks

Institutions

Contact details

David Price

Primary lead investigator
ORCID number:
0000-0002-9728-9992
Study timelines

Date when funding contract was signed

Planned:
Actual:

Study start date

Planned:
Actual:

Data analysis start date

Actual:

Date of final study report

Planned:
Sources of funding
Other
Pharmaceutical company and other private sector 

More details on funding

Pharmaceutical companies: AstraZeneca

Other: Optimum Patient Care Global
Study protocol
Initial protocol

GLEAM_PROTOCOL_Final_25.03.15.pdf

English (622.3 KB - PDF)View document
Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable